Four-year experience with exclusive use of cytomegalovirus antibody (CMV-Ab)-negative donors for CMV-Ab-negative kidney recipients.
Because of unacceptable CMV related morbidity, mortality, and graft loss, we adopted a policy that (-) patients would receive renal allografts only from (-) donors. This policy has resulted in a significant decrease in (1) morbidity (10.6% v 1.7%, P less than .0001), (2) mortality (3.7%) v 0%, P = .002), and (3) graft loss (2.5% v 0%, P = .016). CMV-Ab-negative patients (1) constitute 26% of all patients tested (compared with 36% of all donors tested), (2) receive transplants at the same rate as (+) patients, (3) do not have a prolonged waiting time, and (4) received greater HLA-A, B, -DR mismatched kidneys (3.6 v 3.1, P less than .01).
Ackermann
J R
JR
Department of Surgery, University of South Florida, Tampa.
LeFor
W M
WM
Weinstein
S
S
Kahana
L
L
Shires
D L
DL
Tardif
G
G
Baxter
J
J
D000914:Antibodies, Viral / Q000032:analysis*; D003587:Cytomegalovirus / Q000276:immunology*; D003586:Cytomegalovirus Infections / Q000453:epidemiology / Q000517:prevention & control* / Q000635:transmission; D005431:Florida; D006084:Graft Rejection; D006801:Humans; D016030:Kidney Transplantation; D011183:Postoperative Complications / Q000453:epidemiology / Q000209:etiology / Q000517:prevention & control*
D000914:Antibodies, Viral